US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Paget's Market Research Reports & Industry Analysis

Paget's disease of the bone (other terms are Paget's disease, osteitis deformans, osteodystrophia deformans) is a chronic disorder that typically results in inflated and unshaped bone. The condition is named after Sir James Paget, the British surgeon who first described it in the 19th century. The excessive breakdown and formation of bone tissue that occurs with Paget's disease can cause bone to soften, the result being pain, arthritis, deformities, and fractures.

Paget's disease is not often diagnosed in people less than 40 years of age. Women are more commonly affected than men. Prevalence of Paget's disease ranges from 1.5 to 8.0 percent, depending on age and country of residence. Prevalance of familial Paget's disease (where more than one family member has the disease) ranges from 10 to 40 percent in different parts of the world. Because early diagnosis and treatment is important, after age 40, siblings and children of someone with Paget's disease may wish to have an alkaline phosphatase blood test every two or three years. If the alkaline phosphatase level is abnormal, other tests such as a bone-specific alkaline phosphatase test, bone scan, or X-ray can be performed.

RSS Feeds

Paget's Industry Research & Market Reports

Paget's Disease-API Insights, 2014
11/21/2014 | published by: DelveInsight
... drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market. India and China produce a large percentage of a majority ...  |  read more...
USD 1,250
Paget's Disease- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
11/21/2014 | published by: DelveInsight
... phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries ...  |  read more...
USD 2,000
Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar
6/12/2012 | published by: GBI Research
... has released its latest research, “Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar”, which provides insights ...  |  read more...
USD 3,500